Basal insulin peglispro (BIL) is a novel basal insulin with hepato-preferential action, resulting from reduced peripheral effects. This report summarizes hypoglycaemia data from five BIL phase III studies with insulin glargine as the comparator, including three double-blind trials. Prespecified pooled analyses (n = 4927) included: patients with type 2 diabetes (T2D) receiving basal insulin only, those with T2D on basal-bolus therapy, and those with type 1 diabetes (T1D). BIL treatment resulted in a 36-45% lower nocturnal hypoglycaemia rate compared with glargine, despite greater reduction in glycated haemoglobin (HbA1c) and higher basal insulin dosing. The total hypoglycaemia rate was similar in patients with T2D on basal treatment only, trended towards being higher (10%) in patients with T2D on basal-bolus treatment (p = .053), and was 15% higher (p < .001) with BIL versus glargine in patients with T1D, with more daytime hypoglycaemia in the T1D and T2D groups who were receiving basal-bolus therapy. In T1D, during the maintenance treatment period (26-52 weeks), the total hypoglycaemia rate was not significantly different. There were no differences in severe hypoglycaemia in the T1D or T2D pooled analyses. BIL versus glargine treatment resulted in greater HbA1c reduction with less nocturnal hypoglycaemia in all patient populations, higher daytime hypoglycaemia with basal-bolus therapy in the T1D and T2D groups, and an associated increase in total hypoglycaemia in the patients with T1D.
| INTRODUCTION
Despite advances in insulin therapy, hypoglycaemia remains a significant concern and limits optimization of insulin dosing to achieve glycaemic targets. 1 Hypoglycaemia is associated with increased morbidity and cardiovascular risk. 1 Patients/caregivers may be fearful of nocturnal hypoglycaemia, which may affect sleep and wellbeing. 2 Basal insulin peglispro (BIL) is PEGylated insulin lispro and has a flat pharmacokinetic profile with a 2-3 day half-life. 3 BIL has an hepato-preferential action versus glargine as a result of a reduced peripheral action rather than an enhanced effect on the liver 4 ( Fig 2) . The primary objective of the BIL phase III studies was to demonstrate the non-inferiority of glycated haemoglobin (HbA1c) for BIL versus glargine. The three double-blind studies were also powered for the key secondary objective of superiority of BIL versus glargine for reduction in nocturnal hypoglycaemia rate.
In five phase III IMAGINE trials, BIL treatment met the primary objective of non-inferiority to glargine for HbA1c. [5] [6] [7] [8] [9] The five IMAG-INE trials also resulted in 0.2-0.5% greater HbA1c reduction versus glargine over 26, 52 and 78 weeks in patients with type 1 diabetes (T1D) and those with type 2 diabetes (T2D), meeting the key secondary objective of statistical superiority (with multiplicity adjustment), with higher basal insulin doses.
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The present report summarizes prespecified pooled hypoglycaemia analyses from the IMAGINE studies with a glargine comparator. The 52-week data are presented for IMAGINE 2 and 3 and 26-week data for IMAGINE 4 (Table S1 , Appendix S1).
| METHODS
Analyses (SAS 9.1, Cary, North Carolina) were conducted on the modified intention-to-treat population of all randomized patients who received ≥1 study insulin dose. All tests were conducted at a twosided α value = 0.05 and 95% confidence intervals (CIs) were calculated. Pooling of studies for HbA1c was prespecified. All continuous variables were analysed using mixed linear models with repeated measurements. Total/nocturnal hypoglycaemia frequencies were analysed using negative binomial regression and a model-based rate for each treatment was estimated. 11 The rate of severe hypoglycaemia was analysed using an empirical method; hypoglycaemia incidence was assessed using a logistic regression model or Cochran-MantelHaenszel test (if <10 patients with events). Analysis of variance was used for continuous variables collected at baseline.
| RESULTS
A total of 4927 patients randomized to bedtime BIL (n = 2949) or glargine (n = 1978) were included. Baseline characteristics were similar between groups (Table 1) . Across the studies, 49-72% of patients with T2D and 64-71% of patients with T1D were previously treated with glargine.
The pooled analyses were consistent with the individual study results, with a 0.21-0.33% greater reduction in HbA1c with BIL versus glargine (Table 1) .
Basal insulin doses were 10-24% higher with BIL versus glargine across phase III studies (Table 1) . [5] [6] [7] [8] [9] Bolus insulin doses were 27% lower with BIL versus glargine in T1D (Table 1 ), but not statistically significantly different in patients with T2D receiving basal-bolus insulin (Table 1) . 6 Nocturnal hypoglycaemia rates were reduced by 36% in patients with T2D on basal insulin only, 45% in patients with T2D on basalbolus insulin, and 43% in patients with T1D with BIL versus glargine ( Figure 1A ). Nocturnal hypoglycaemia incidence was statistically significantly lower with BIL versus glargine in all patient populations ( Figure 1B) . The nocturnal hypoglycaemia rate and incidence sensitivity analyses were consistent with the primary results including: prespecified analyses of the alternative nocturnal hypoglycaemia definition for basal only and basal-bolus e-diary studies and post hoc analyses including events between 00:01 and 05:59 hours ( Figure S1 , Appendix S1).
The total hypoglycaemia rate was not significantly different in patients with T2D on basal insulin only, there was a 10% higher trend in patients with T2D on basal-bolus insulin (p = .053), and the rate was 15% higher in patients with T1D (p < .001) with BIL versus glargine ( Figure 1C ). The total hypoglycaemia incidence was not different between treatments in any population ( Figure 1D ). In patients with T1D or T2D on basal-bolus insulin, daytime hypoglycaemia was significantly higher with BIL versus glargine ( Figure 1E ) from 0 to 52 and 0 to 26 weeks, respectively. In T1D patients, during the maintenance period of 26-52 weeks, the total hypoglycaemia relative rate (BIL/glargine) was 1.07 (95% CI 1.00, 1.14; p = .062; Figure S2 , Appendix S1).
There were no significant differences in the rate or incidence of severe hypoglycaemia between treatments in all three patient populations ( Figure 1F and G).
In the three double-blind studies, CGM was performed in patient subsets (BIL, n = 313, glargine, n = 215). In patients with T1D or T2D, there were no significant treatment differences in duration with glucose level ≤3.9 mmol/L (00:00-06:00 hours or over 24 hours) or in the average duration of individual hypoglycaemic episodes with BIL versus glargine (Table S1 , Appendix S1).
| DISCUSSION
The present analyses provide a summary of prespecified and pooled hypoglycaemia analyses from the five IMAGINE studies with glargine comparator. BIL treatment resulted in a 36-45% reduction in nocturnal hypoglycaemia rate versus glargine, despite greater reduction in HbA1c and higher basal insulin dosing. There was a 15% increase in total hypoglycaemia in T1D with an associated increase in daytime hypoglycaemia with basal-bolus therapy in T1D and T2D.
CGM in patient subsets showed no evidence of prolongation or shortening of hypoglycaemic episodes with BIL versus glargine.
There were no significant differences in severe hypoglycaemia among the three populations. Nocturnal hypoglycaemia was also reduced with morning dosing of BIL versus glargine in T1D and T2D phase II studies 12, 13 and nocturnal/total hypoglycaemia were similar with bedtime versus 8-40-hours variable-time dosing of BIL in a T1D phase III study.
14 The significant reduction in nocturnal hypoglycaemia was achieved simultaneously with greater improvements in HbA1c with BIL versus glargine. In contrast, significant reductions in nocturnal hypoglycaemia rates were reported in clinical studies of insulin degludec 15 and glargine U-300 16 versus glargine U-100, but with noninferiority of HbA1c. This may reflect the hepato-preferential action of BIL as well as longer duration of action, lower peak-to-trough ratio, and reduced glucose variability versus glargine U-100 seen across the BIL phase III trials. [5] [6] [7] [8] [9] A study in the conscious dog has shown that peripheral insulin delivery increased hypoglycaemia risk versus portal vein insulin delivery, suggesting that hepato-preferential insulin analogues may be associated with a lower risk of hypoglycaemia. 17 Glucose variability has also been independently associated with the risk of hypoglycaemia. 18, 19 Increased daytime hypoglycaemia with BIL versus glargine in basal-bolus therapy may also reflect the hepato-preferential action and longer duration of action of BIL. In T1D, the adjustment of basalbolus dosing occurred gradually during the titration period and resulted in significantly reduced bolus insulin requirements with BIL compared with glargine. During the maintenance period of 26-52 weeks and after basal-bolus dose adjustment and stabilization, total hypoglycaemia decreased in T1D and was not significantly different between groups ( Figure S2 , Appendix S1).
The strengths of the present pooled analyses of five BIL phase III studies include the double-blind design of three trials, which were also powered to detect differences in nocturnal hypoglycaemia, the large sample size of >4900 patients, as well as the global nature of the studies. The use of an e-diary in three basal-bolus studies 
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Nocturnal Hypoglycemia Incidence FIGURE 1 Nocturnal, total, daytime and severe hypoglycaemia. A, Nocturnal hypoglycaemia rate per patient-year AE standard error (s.e.). B, Nocturnal hypoglycaemia incidence. C, Total hypoglycaemia rate per patient-year AE s.e. D, Total hypoglycaemia incidence. E, Daytime hypoglycaemia rate per patient-year AE s.e. F, Severe hypoglycaemia rate per 100 patient-years. Values are aggregated rate, calculated using the total number of severe hypoglycaemia episodes divided by the cumulative days on treatment from all patients within that treatment, then times 36 525 days (for rate per 100 years). G, Severe hypoglycaemia incidence. Weeks of study data included: T2D basal only (0-52 weeks), T2D basal-bolus (0-26 weeks), T1D (0-52 weeks). B, basal only; BB, basal-bolus; GL, insulin glargine; RR, relative rate. *p < .05 for betweentreatment-group comparisons.
